160 related articles for article (PubMed ID: 29034756)
1. A prediction model for early death in non-small cell lung cancer patients following curative-intent chemoradiotherapy.
Jochems A; El-Naqa I; Kessler M; Mayo CS; Jolly S; Matuszak M; Faivre-Finn C; Price G; Holloway L; Vinod S; Field M; Barakat MS; Thwaites D; de Ruysscher D; Dekker A; Lambin P
Acta Oncol; 2018 Feb; 57(2):226-230. PubMed ID: 29034756
[TBL] [Abstract][Full Text] [Related]
2. Developing and Validating a Survival Prediction Model for NSCLC Patients Through Distributed Learning Across 3 Countries.
Jochems A; Deist TM; El Naqa I; Kessler M; Mayo C; Reeves J; Jolly S; Matuszak M; Ten Haken R; van Soest J; Oberije C; Faivre-Finn C; Price G; de Ruysscher D; Lambin P; Dekker A
Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):344-352. PubMed ID: 28871984
[TBL] [Abstract][Full Text] [Related]
3. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
4. Developing and validating an integrated gross tumor volume (GTV)-TNM stratification system for supplementing unresectable locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Chen NB; Li QW; Zhu ZF; Wang YM; Cheng ZJ; Hui ZG; Guo SP; He HQ; Wang B; Huang XY; Li JB; Guo JY; Hu N; Ai XL; Zhou Y; Wang DQ; Liu FJ; Xie CM; Qiu B; Liu H
Radiat Oncol; 2020 Nov; 15(1):260. PubMed ID: 33168045
[TBL] [Abstract][Full Text] [Related]
5. External validation of an NTCP model for acute esophageal toxicity in locally advanced NSCLC patients treated with intensity-modulated (chemo-)radiotherapy.
Dankers FJWM; Wijsman R; Troost EGC; Tissing-Tan CJA; Kwint MH; Belderbos J; de Ruysscher D; Hendriks LE; de Geus-Oei LF; Rodwell L; Dekker A; Monshouwer R; Hoffmann AL; Bussink J
Radiother Oncol; 2018 Nov; 129(2):249-256. PubMed ID: 30241789
[TBL] [Abstract][Full Text] [Related]
6. Predictive model of the first failure pattern in patients receiving definitive chemoradiotherapy for inoperable locally advanced non-small cell lung cancer (LA-NSCLC).
Zhu X; Hou R; Li X; Jiang C; Xia W; Fu X
Radiat Oncol; 2020 Feb; 15(1):43. PubMed ID: 32070383
[TBL] [Abstract][Full Text] [Related]
7. A comparison of machine learning methods for predicting recurrence and death after curative-intent radiotherapy for non-small cell lung cancer: Development and validation of multivariable clinical prediction models.
Hindocha S; Charlton TG; Linton-Reid K; Hunter B; Chan C; Ahmed M; Robinson EJ; Orton M; Ahmad S; McDonald F; Locke I; Power D; Blackledge M; Lee RW; Aboagye EO
EBioMedicine; 2022 Mar; 77():103911. PubMed ID: 35248997
[TBL] [Abstract][Full Text] [Related]
8. The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy.
Koo TR; Moon SH; Lim YJ; Kim JY; Kim Y; Kim TH; Cho KH; Han JY; Lee YJ; Yun T; Kim HT; Lee JS
Radiat Oncol; 2014 Dec; 9():283. PubMed ID: 25498887
[TBL] [Abstract][Full Text] [Related]
9. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
Ohri N; Piperdi B; Garg MK; Bodner WR; Gucalp R; Perez-Soler R; Keller SM; Guha C
Lung Cancer; 2015 Jan; 87(1):23-7. PubMed ID: 25468149
[TBL] [Abstract][Full Text] [Related]
10. Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial.
Guberina M; Eberhardt W; Stuschke M; Gauler T; Heinzelmann F; Cheufou D; Kimmich M; Friedel G; Schmidberger H; Darwiche K; Jendrossek V; Schuler M; Stamatis G; Pöttgen C
Ann Oncol; 2017 May; 28(5):1084-1089. PubMed ID: 28453703
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325).
Dehing-Oberije C; Aerts H; Yu S; De Ruysscher D; Menheere P; Hilvo M; van der Weide H; Rao B; Lambin P
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):360-8. PubMed ID: 20888135
[TBL] [Abstract][Full Text] [Related]
12. Systemic immune-inflammation index changes predict outcome in stage III non-small-cell lung cancer patients treated with concurrent chemoradiotherapy.
Huang T; Zhang H; Zhao Y; Li Y; Wang G; Zhang Y; Guo D; Ji S; Sun Z
Future Oncol; 2021 Jun; 17(17):2141-2149. PubMed ID: 33635094
[No Abstract] [Full Text] [Related]
13. Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy.
Dehing-Oberije C; Yu S; De Ruysscher D; Meersschout S; Van Beek K; Lievens Y; Van Meerbeeck J; De Neve W; Rao B; van der Weide H; Lambin P
Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):355-62. PubMed ID: 19095367
[TBL] [Abstract][Full Text] [Related]
14. Overall survival and toxicities regarding thoracic three-dimensional radiotherapy with concurrent chemotherapy for stage IV non-small cell lung cancer: results of a prospective single-center study.
Su SF; Hu YX; Ouyang WW; Lu B; Ma Z; Li QS; Li HQ; Geng YC
BMC Cancer; 2013 Oct; 13():474. PubMed ID: 24118842
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
Jabbour SK; Berman AT; Decker RH; Lin Y; Feigenberg SJ; Gettinger SN; Aggarwal C; Langer CJ; Simone CB; Bradley JD; Aisner J; Malhotra J
JAMA Oncol; 2020 Jun; 6(6):848-855. PubMed ID: 32077891
[TBL] [Abstract][Full Text] [Related]
16. Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis.
Rodrigues G; Oberije C; Senan S; Tsujino K; Wiersma T; Moreno-Jimenez M; Kim TH; Marks LB; Rengan R; De Petris L; Ramella S; DeRuyck K; De Dios NR; Warner A; Bradley JD; Palma DA
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):133-9. PubMed ID: 25835622
[TBL] [Abstract][Full Text] [Related]
17. The survival outcomes and prognosis of stage IV non-small-cell lung cancer treated with thoracic three-dimensional radiotherapy combined with chemotherapy.
Su S; Hu Y; Ouyang W; Ma Z; Lu B; Li Q; Li H; Wang Z; Wang Y
Radiat Oncol; 2014 Dec; 9():290. PubMed ID: 25518882
[TBL] [Abstract][Full Text] [Related]
18. SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status.
Maguire J; Khan I; McMenemin R; O'Rourke N; McNee S; Kelly V; Peedell C; Snee M
Eur J Cancer; 2014 Nov; 50(17):2939-49. PubMed ID: 25304298
[TBL] [Abstract][Full Text] [Related]
19. Radical radiotherapy or chemoradiotherapy for inoperable, locally advanced, non-small cell lung cancer: Analysis of patient profile, treatment approaches, and outcomes for 213 patients at a tertiary cancer center.
Shrimali RK; Nallathambi C; Saha A; Das A; Prasath S; Mahata A; Arun B; Mallick I; Achari R; Dabkara D; Thambudorai R; Chatterjee S
Indian J Cancer; 2018; 55(2):125-133. PubMed ID: 30604722
[TBL] [Abstract][Full Text] [Related]
20. Concurrent vs sequential chemoradiotherapy for patients with advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials.
Xiao W; Hong M
Medicine (Baltimore); 2021 Mar; 100(11):e21455. PubMed ID: 33725921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
